Prilenia Report issue

For profit Phase 3
Founded: Herzliya Israel (2018)

Organization Overview

First Clinical Trial
2019
NCT03922711
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Prilenia | Prilenia Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

pridopidine (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Dyskinesias (Phase 2)

Huntington Disease (Phase 3)

Motor Neuron Disease (Phase 3)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1